Hepatitis B Virus DNA in Sera of Blood Donors and of Patients Infected with Hepatitis C Virus and Human Immunodeficiency Virus

Gonçales, Fernando Lopes; Pereira, Josiane Silveira Felix; Silva, Cláudia Bezerra da; Thomaz, Glaucimari Roberto; Pavan, Maria Helena Postal; Fais, Viviane Cristina; Magna, Luís Alberto; Gonçales, Neiva Sellan Lopes

doi:10.1128/cdli.10.4.718-720.2003

Cited by 22 publications

(20 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the significance in the study, as a liver function test alone it is not sensitive nor specific, but in patients with chronic hepatic disease it can be used together with other tests as a noninvasive manner of determining the diagnosis and prognosis of the patients, as has also been described by other authors [27] (Figure 11). Mean values of alpha-fetoprotein in this study were 14.03 ± 26 IU/mL in patients with hepatitis and 4.92 ± 0.3 IU/mL in carriers, with a significant association between this marker and the presence of hepatitis, where hepatocarcinoma was detected in 3.63% of the patients with hepatitis and cirrhosis, confirming studies of other authors who showed that alphafetoprotein is an important laboratory test in the screening for hepatocellular carcinoma (CHC), but its elevation is not obligatory in CHC since 20% to 30% of the cases have normal values of this protein [29]. Other authors observed a similar incidence of CHC in HBsAg-positive patients after HBeAg seroconversion [10].…”

Section: Clinico-epidemiological Manifestationssupporting

confidence: 73%

Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia

Victoria¹,

Oliveira²,

Victoria³

et al. 2008

Braz J Infect Dis

View full text Add to dashboard Cite

The present study was conducted with 55 patients native from western Brazilian Amazonia, who were HBV-DNA positive after seroconversion of HBeAg. It is a descriptive case study, with the patients separated into two groups: with hepatitis and without hepatitis on histological examination. The aim of the present study was to describe the clinical and molecular characteristics of patients who are chronic carriers of HBsAg. The prevalence of hepatitis was 63.64%, with a predominance of males (41.82%) and a mean age of 42.5 years, occurring mostly in natives of the southeast sub-region (32.73%). Time was a variable proportional to the course of the disease and the most frequent symptoms were: dyspepsia, asthenia and loss of libido with the majority of the patients having history of prior contact with HBV or positive family history. Splenomegalia was the most frequent sign (40%). Among the tests, platelet count, serum albumin and prothrombin activity were significant in the diagnosis of hepatitis. Alphafetoprotein was greater in patients with hepatitis, and hepatocellular carcinoma was detected in 3.63% of the patients with hepatic cirrhosis. Three types of HBV genotypes were diagnosed: A, D and F in the samples amplified for gene S. Genotype A (AA) was observed in 54.54% of the cases with hepatitis, in contrast to other studies showing the predominance of genotype F in this region. We observed mutations in 36.36%, with a predominance of the mutations in the core promoter region (31.81%), due to the greater prevalence of genotype A in this study. Key-Words: HBeAg-negative chronic hepatitis B, western Brazilian Amazonia, mutations.Western Brazilian Amazonia is considered a region of high endemicity for hepatitis B virus (HBV), where a large part of the population is infected in perinatal period and during infancy. The prevalence of chronic carriers of HBV surface antigen (HBsAg) in these areas varies between 5% and 15% and approximately 50% to 95% of the population show serologic evidence of past infection with HBV [1,2,3]. Various factors are implicated in the development and outcome of HBV infection, but the progression to chronic hepatitis is proportionally greater in individuals infected by the vertical route or during the perinatal period [4]. Chronic hepatopathies related to HBV are seen in two forms: HBeAg positive and HBeAg negative. The HBeAg-negative chronic forms are represented by two groups of patients: chronic inactive HBsAg carriers and chronic hepatitis B (CHB) patients. The distinction between these two forms is difficult, particularly in patients with biochemical and intermittent virologic activity. It is estimated that in the world there are approximately 350 million inactive HBsAg carriers, and of these, 7% to 30% are infected with mutant forms of HBV, which despite the presence of anti-HBe antibody continue to be HBV-DNA positive [5]. Chronic HBsAg carriers who show HBeAg-negative/antiHBe-positive serologic status and have serum HBV-DNA detectable by PCR and active hepatic disease characterized by ...

show abstract

Section: Clinico-epidemiological Manifestationssupporting

confidence: 73%

Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia

Victoria¹,

Oliveira²,

Victoria³

et al. 2008

Braz J Infect Dis

View full text Add to dashboard Cite

show abstract

“…Occult hepatitis prevalence data reported in "antiHBs alone" HIV-positive patients varies greatly from 0% to 89.5% [1][2][3]9,12,17,20,21] . However, in those studies that have found viral replication, detected viral load was usually very low (< 10 3 copies/mL) [3,20] .…”

Section: Discussionmentioning

confidence: 99%

“…Clinical relevance and management of this low viral replication is unclear because a higher incidence of hepatic damage was not found in these patients [16] . On the other hand, current therapeutic guidelines do not recommend starting treatment if the viral load is lower than 10 4 -10 5 copies/ mL [6,[21][22][23][24] . More than 90% of doctors that attend HIV patients follow this practice [22] .…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients

Pérez-Rodríguez

Sopeña²,

Crespo³

et al. 2009

WJG

View full text Add to dashboard Cite

AIM:To determine the prevalence and clinical relevance of isolated antibodies to hepatitis B core antigen as the only marker of infection ("anti-HBc alone") among human immunodeficiency virus (HIV) type-1 infected patients. Occult hepatitis B infection frequency was also evaluated. METHODS:Three hundred and forty eight histories from 2388 HIV-positive patients were randomly reviewed. Patients with serological markers of hepatitis B virus (HBV) infection were classified into three groups: past hepatitis, "anti-HBc alone" and chronic hepatitis. Determination of DNA from HBV, and RNA and genotype from hepatitis C virus (HCV) were performed on "anti-HBc alone" patients.

show abstract

“…In fact, the published prevalence ranges from 0% to 89% [73,74], with a considerable number of other studies reporting results between those two extremes [75][76][77][78][79][80][81][82][83] ( Table 2). The great difference in sensitivity and specificity of the assays used in these various studies has already been denounced in a previous review [84].…”

Section: Prevalencementioning

confidence: 95%

Occult hepatitis B virus infection

Raimondo¹,

Pollicino²,

Cacciola³

et al. 2007

Journal of Hepatology

452

295

View full text Add to dashboard Cite

Hepatitis B Virus DNA in Sera of Blood Donors and of Patients Infected with Hepatitis C Virus and Human Immunodeficiency Virus

Cited by 22 publications

References 15 publications

Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia

Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia

Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients

Occult hepatitis B virus infection

Contact Info

Product

Resources

About